Direct costs of brain disorders make up for 60% of the total costs – which EBC estimated at 800 bln€/year in Europe. At European level, this health budget far exceeds that of cardiovascular diseases, brain diseases and diabetes together. ALAMEDA will research, develop and exploit the next generation of personalized AI healthcare support systems that improve the rehabilitation treatment of Parkinson’s, Multiple Sclerosis, and Stroke (PMSS) patients. Stemming from very specific clinical use cases, ALAMEDA will develop user-friendly solutions that will be designed and evaluated on the principles of value-based health. The consortium brings together established medical research teams, AI researchers, medical software vendors and healthcare market experts to demonstrate AI-based personalised prediction, prevention, and intervention approach in three (3) real world pilots. Liaisons have been established with projects MULTI-ACT and IDEA-FAST and the carefully structured workplan, embodies an integrated and harmonized approach with active patients’ engagement towards meeting the ALAMEDA objectives and delivering market-relevant outcomes of significant exploitation potential.

Focusing on chronic respiratory conditions (CRDs), LMICs pay an unfairly high cost in terms of morbidity and mortality. Along with the existence of CRDs, other multiple long-term chronic conditions co-exist, including ischemic heart disease, hypertension, diabetes, osteoporosis and depression. Current care in these countries presents significant shortcomings such as the limited availability of affordable and user-friendly digital tools for remote monitoring and patient engagement, while care fragmentation is even more evident creating substantial inequality to the health services and outcomes, greatly affecting their Universal Health Coverage. In this direction, the 48-month implementation research-driven MULTIPULM project aims to apply an integrated care digital-based ecosystem, consisting of evidence-based tools, for effectively managing long-term conditions and enhancing secondary prevention of multimorbid patients suffering from chronic respiratory conditions with the focus on LMIC countries of Brazil, Serbia and Türkiye. MULTIPULM approach and offerings aim to improve the QoL of patients and their families as well as tackle the social, financial, political and organizational disparities linked with high challenging management of multimorbidity, formulating a reference paradigm for other LMICs to follow. The successful implementation of the integrated care models paradigms will be orchestrated by a meticulous detailed implementation roadmap and local capacity building activities for the creation of a critical mass of local stakeholders. In this light, MULTIPULM will be validated at large-scale with 3200 multimorbid patients in the 3 targeted LMIC countries. Last but not least, a socio-economic and financial assessment is scheduled to support local policy makers in the continuation of the project activities beyond its duration, contributing to the long-term sustainability of its benefits and to the improvement of the targeted countries’ UHC index.

The health sector is steadily becoming the de facto target for cyberattacks. Based on the most recent ENISA report at the end of 2018, cybersecurity incidents have shown that the healthcare sector is one of the most vulnerable. Focusing specifically on Electronic Medical Devices (EMD), they suffer from numerous and multi-layered vulnerabilities . Default, weak or no password authentication for remote connections, unencrypted traffic or obsolete and insecure cryptographic algorithms, unsupported operating systems, outdated, unmanaged and vulnerable software are among the most serious problems that jeopardise both their smooth operation and the data aggregated and stored. The vision of HEIR is to provide a thorough threat identification and cybersecurity knowledge base system addressing both local (in the hospital / medical centre) and global (including different stakeholders) levels, that comprises the following pillars: (i) Real time threat hunting services, facilitated by advanced machine learning technologies, supporting the identification of the most common threats in electronic medical systems based on widely accepted methodologies such as the OWASP Top 10 Security Risks and the ENISA Top 15 Threats; (ii) Sensitive data trustworthiness sharing facilitated by the HEIR privacy aware framework; (iii) Innovative Benchmarking based on the calculation of the Risk Assessment of Medical Applications (RAMA) score, that will measure the security status of every medical device and provide thorough vulnerability assessment of hospitals and medical centres; (iv) The delivery of an Observatory for the Security of Electronic Medical Devices; an intelligent knowledge base accessible by different stakeholders, providing advanced visualisations for each threat identified in RAMA and facilitating global awareness on EMD-related threats. Last, HEIR will set up a broad European network for establishing good security practice in all regulatory frameworks to reduce market access.

Lung related diseases such as chronic obstructive pulmonary disease (COPD), pneumonia and asthma are considered the main causes of death in the EU. The current management of such diseases only allows a momentary patient assessment at the time point of out-clinic visit or hospitalization. Short-term trends in disease development, either deterioration or improvement, are not accessible. Continuous and real-time monitoring, especially in remote settings (e.g. patients’ homes) is not available. Additionally the devices used for monitoring the patients are massive, expensive, uncomfortable and difficult to operate, thus requiring specialized personnel. Several of them also rely on patients´ cooperation and compliance to guarantee proper examination results. The incorporation of novel electronics in garments presents great potential for addressing these challenges. More specifically, the adoption of Application-Specific-Integrated-Circuits (ASICs) neatly integrated in a comfortable and washable wearable is the key that makes the accurate and effective (in terms of both, cost and quality of life) continuous monitoring of lung diseases feasible. The 42-month project WELMO aims at developing and validating a new generation of low-cost and low-power miniaturized sensors, integrated in a comfortable vest, enabling the effective and accurate monitoring of the lungs, through the simultaneous collection of sound and electrical impedance tomography (EIT) signals with the same sensors that can be combined, processed and linked with specific clinical outcomes by applying innovative algorithms, making the systematic, accurate and real-time evaluation of respiratory conditions possible. The impact, acceptance and usability of WELMO will be validated in a realistic setup through the execution of two 6-month pilot studies. In addition, a business study will be carried out, aiming to the mid-term exploitation of the proposed solution.